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Abstract: Background: To compare early visual changes in amyotrophic lateral sclerosis (ALS)
patients with healthy controls in a baseline exploration, to follow-up the patients after 6 months,
and to correlate these visual changes with neurological disability. Methods: All patients underwent
a comprehensive neurological and ophthalmological examination. A linear mixed analysis and
Bonferroni p-value correction were performed, testing four comparisons as follows: Control baseline
vs. control follow-up, control baseline vs. ALS baseline, control follow-up vs. ALS follow-up,
and ALS baseline vs. ALS follow-up. Results: The mean time from the diagnosis was 10.80 ± 5.5
months. The analysis of the optical coherence tomography (OCT) showed: (1) In ALS baseline vs.
control baseline, a macular significantly increased thickness of the inner macular ring temporal and
inferior areas; (2) in ALS follow-up vs. ALS baseline, a significant macular thinning in the inner and
outer macular ring inferior areas; (3) in ALS follow-up vs. ALS baseline, a significant peripapillary
retinal nerve fiber layer (pRNFL) thinning in the superior and inferior quadrants; and (4) ALS
patients showed a moderate correlation between some OCT pRNFL parameters and Amyotrophic
Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score. Conclusion: The OCT showed
retinal changes in patients with motoneuron disease and could serve as a complementary tool for
studying ALS.
Keywords: amyotrophic lateral sclerosis; ALS; OCT; retina; Optic nerve; eye; neurodegenerative
1. Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of progressive motor neuron disease.
Worldwide, the incidence of ALS ranges from 0.3 to 2.5 cases per year per 100,000 people [1]. It is
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more common in men than in women, with a ratio of 1.5:1 [1]. ALS is a neurodegenerative disease
characterized by rapid progression, which affects first and second motor neurons to different degrees,
causing muscle fiber atrophy. Patients with ALS die within two to three years from diagnosis, usually
due to respiratory failure [1,2]. Classically, eye motor nuclei were thought to be unaffected. However,
some studies have found abnormal ocular movements in these patients [3–5]. No single specific test
exists for ALS diagnosis; it is a diagnosis of exclusion based on the initial symptoms, the progression of
the disease, and tests to eliminate overlapping conditions. Finally, the degree of neurological disability
is determined by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) [6].
To date, many studies have focused on assessing the possible participation of non-motor areas of
the central nervous system (CNS) in ALS [7–11]. These patients have demonstrated [7]:
(1) An overall reduction in brain volume [10,11], with a loss of focal grey matter and changes in
white matter in non-motor areas [9,12];
(2) Cognitive impairment [8];
(3) Small fiber neuropathy [13];
(4) Abnormal evoked potentials [14–17];
(5) Oculomotor dysfunction [3,4,18–20]; and
(6) Astrogliosis in non-motor areas, specifically in the occipital area [21].
Optical coherence tomography (OCT) is a non-invasive imaging technique that is accurate,
objective, and reproducible. OCT can provide high-resolution images of retinal layers [22] and detect
neuroaxonal retinal abnormalities in many neuroinflammatory and neurodegenerative diseases [23–39].
Some researchers have analyzed changes in the visual pathway (a non-motor neuron area) using OCT
in ALS patients [7,40–45]. These studies are not homogeneous because they included not only different
clinical symptoms of ALS (bulbar, frontotemporal dementia, or spinal onset), but also different stages
of disease progression. Therefore, the results, in many cases, are contradictory. All these works are
cross-sectional without patient follow-up. Longitudinal studies are needed to further investigate the
temporal evolution of ALS in the retina and the optic nerve.
The aims of this study were to compare early visual changes in ALS patients with healthy controls
in a baseline exploration, to follow up with the patients after 6 months, and to correlate these visual
changes with neurological disability.
2. Material and Methods
2.1. Participants: Study Groups and Selection Criteria
The study protocol adhered to the tenets of the Helsinki Declaration and was approved by the
Gregorio Marañón Hospital (HGUGM) Ethical Committee (NCT03285204). Each subject provided
written informed consent before entering the study.
This prospective study was conducted at the HGUGM and Ramón Castroviejo Ophthalmologic
Research Institute in the Complutense University of Madrid, Spain. Patients were diagnosed in the
ALS-neuromuscular unit of the Neurology Department, based on El Escorial criteria [46]. We performed
the ophthalmological examination only if patients met the following criteria: (1) Being diagnosed in
the first 18 months after the onset of the motor symptoms, (2) having spinal onset, (3) being sporadic
ALS, and (4) not having clinical cognitive impartment. Only 10 ALS patients fulfilled these criteria.
Thus, we selected 20 eyes from the 10 ALS patients (ALS baseline group). We were only able to
follow-up with 5 out of the 10 initial patients due to very poor health conditions or death by respiratory
distress or intercurrent diseases. Therefore, we studied the 10 eyes of these 5 patients (ALS follow-up
group). The control group was selected from the patients’ relatives, mainly the spouse, and volunteers.
We studied 38 eyes from 19 healthy controls (control baseline group) and followed up with them after
6 months (control follow-up group).
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2.2. Study Protocol
A multidisciplinary team examined each patient. This team included neurologists, pulmonologists,
and ophthalmologists. All patients underwent an exhaustive complete neurological examination,
including the ALSFRS-R scale, with the same neurologist [6]. For ophthalmological examination, both
eyes of each patient were analyzed. All participants, ALS and controls, met the following inclusion
criteria: (1) Being free of ocular disease, (2) Evaluation of Aged-Related Eye Disease (AREDS) Clinical
Lens Standards <2, (3) being free of systemic disorders affecting vision, (4) having a best corrected
visual acuity (BCVA) of more than 20/40, (5) having less than ±5 sphere–cylindrical refractive error,
and (6) having intraocular pressure (IOP) less than 20 mmHg.
For screening, all ALS patients and control subjects underwent a complete ophthalmologic
examination, including an assessment of BCVA, refraction, anterior segment biomicroscopy,
measurement of intraocular pressure (IOP) with Goldman applanation tonometer (AT900, Haag-Streit,
Köniz, Switzerland), dilated fundus examination, and a spectral-domain Cirrus HD-OCT Model 4000
(Carl Zeiss Meditec, Dublin, CA, USA; software version 6.2) analysis using Optic Disc 200 × 200 and
Macular cube 512 × 128 scanning protocols [47,48]. Macular thickness (MT), ganglion cell complex
(GCC), cube volume, average cube thickness, and peripapillary retinal nerve fiber layer (pRNFL)
thickness were measured via OCT Cirrus after pupil dilation. The mean values were considered for
statistical analysis. All tests were performed by the same ophthalmologist under the same conditions
for the baseline evaluation and the follow-up (after 6 months).
As in the Early Treatment Diabetic Retinopathy Study (ETDRS) [47], MT data were displayed in
three concentric rings centered in the fovea. These rings were distributed as follows: A central macular
thickness (CMT) with a diameter of 1 mm, an inner macular ring (IMR) with a diameter of 3 mm, and an
outer macular ring (OMR) with a diameter of 6 mm. The inner and outer rings were each divided into
four quadrants (superior, inferior, nasal, and temporal). The total volume of the macula, as determined
using OCT, was also used. The GCC covers two inner layers of the retina: IPL (inner plexiform layer)
and GCL (ganglion cell layer), which were measured by special segmentation software provided by
Cirrus HD-OCT Model 4000 (Carl Zeiss Meditec, Dublin, CA, USA; software version 6.2), checked
by the ophthalmologist and re-centered if needed. The pRNFL average thickness was measured.
Peripapillary RNFL was also segmented into four quadrants (superior, temporal, inferior, and nasal),
and in 12 clock hours (H) (H3 denoting nasal, H6 inferior, H9 temporal, and H12 superior in a right
eye). Left eyes (LE) were converted to right eyes (RE) with a specular image (Figure 1). The analyzed
area was centered manually and the absence of segmentation errors was confirmed for each scan.
A good scan was one that met the criterion of a signal-to-noise ratio (SNR) >7/10. All measurements
are provided in microns (µm), according to the calibration provided by the manufacturers, and the
total volume in cubic millimeters (mm3).
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Figure 1. Optic coherence tomography (OCT) analysis of the retina: (A) Coding for the macular Early 
Treatment Diabetic Retinopathy Study (ETDRS) grid, (B) ganglion cell complex (GCC) parameters, 
and (C) peripapillary retinal nerve fiber layer (pRNFL) thicknesses. OD: Right eye; OI: Left eye; CMT: 
Central macular thickness; ILM: Inner limiting membrane; RPE: Retinal pigment epithelium; Sup: 
Superior; SN: Supero-nasal; IN: Infero-nasal; Inf: Inferior; IT: Infero-temporal; ST: Supero-temporal; 
GCL: Ganglion cell layer; IPL: Inner plexiform layer; µm: Microns; H: Clock-hour position. 
Visual fields (VFs) were analyzed using a Humphrey Field Analyzer 750i (Humphrey Zeiss 
Systems, Dublin, CA, USA; 24-2) with the Swedish interactive threshold algorithm (SITA) Fast 24-2 
strategy. Mean deviation (MD), pattern standard deviation (PSD), and visual field index (VFI) were 
used as perimetric indices of generalized sensitivity loss. Localized scotomas and percentages of 
useful residual vision of the patient were studied. A scotoma was defined as a cluster of at least three 
points with lower sensitivity than normal values (including two or more points with a p-value of less 
than 0.5%) on the pattern deviation probability map of the Humphrey Field Analyzer 750i 
(Humphrey Zeiss Systems, Dublin, CA, USA; 24-2) 24-2 SITA-Fast program. Points with diminished 
sensitivity adjacent to the blind spot were not considered parts of scotomas [49]. 
2.3. Statistical Analysis 
Data for the statistical analysis were introduced and processed in SPSS 23.0 (SPSS Inc.©, IBM 
Corporation, Somers, NY, USA) and StataCorp. 2015 (Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LLC, College Station, TX, USA). 
Minimum sample size for each group was estimated in seven eyes (ratio of sample sizes in the 
control group/ALS group = 1) on the basis of a difference in the average pRNFL thickness of 25.1 µm 
and standard deviations (SDs) of 10.3 and 10.9, a type 1 error rate of 0.05, and a power of 95% 
(MedCalc software). Difference of pRNFL thickness based on Ferreras et al.’s study [50]. 
  
Figure 1. Optic coherence tomography (OCT) analysis of the retina: (A) Coding for the macular Early
Treatment Diabetic Retinopathy Study (ETDRS) grid, (B) ganglion cell complex (GCC) parameters,
and (C) peripapillary retinal nerve fiber layer (pRNFL) thicknesses. OD: Right eye; OI: Left eye; CMT:
Central macular thickness; ILM: Inner limiting membrane; RPE: Retinal pigment epithelium; Sup:
Superior; SN: Supero-nasal; IN: Infero-nasal; Inf: Inferior; IT: Infero-temporal; ST: Supero-temporal;
GCL: Ganglion cell layer; IPL: Inner plexiform layer; µm: Microns; H: Clock-hour position.
Visual fields (VFs) were analyzed using a Humphrey Field Analyzer 750i (Humphrey Zeiss
Systems, Dublin, CA, USA; 24-2) with the Swedish interactiv threshold algorithm (SITA) Fast 24-2
strategy. Mea deviation (MD), pa tern standard deviation (PSD), an visual field index (VFI) were
used as perimetric indices of generalized sensitivity loss. Localized scotomas and percentages of useful
r sidual vision of the patient w r studied. A cotoma was defined as a cluster of at least three points
with lower sensitivity t an normal values (including wo or mor points with a p-value of less than
0.5%) on the patter deviation probability map of the Humphrey Field Analyzer 750i (Humphrey Zeiss
Systems, Dublin, CA, USA; 24-2) 24-2 SITA-Fast progr m. Points with diminished sensitivity adjacent
to the blind spot wer not considered parts of scotomas [49].
2.3. Statistical Analysis
Data for the statistical analysis were introduced and processed in SPSS 23.0 (SPSS Inc.©,
IBM Corporation, Somers, NY, USA) and StataCorp. 2015 (Stata Statistical Software: Release 14.
College Station, TX: StataCorp LLC, College Station, TX, USA).
Minimum sample size for each group was estimated in seven eyes (ratio of sample sizes in the
control group/ALS group = 1) on the basis of a difference in the av rage pRNFL thickne s of 25.1 µm
and standard deviati ns (SDs) of 10.3 nd 10.9, a typ 1 rror rate of 0.05, and a power of 95% (MedCalc
software). Diff rence of pRNFL thickness based on Ferreras et al.’s study [50].
The norm lity of distribution was assessed with the Kolmogorov–Smirnov test. Non-parametric
tests were used because data were not normally distributed. A mixed linear analysis was used, both in
the baseline and the follow-up analysis, in order not to overestimate the statistical power of the results
because both eyes of the patients were considered for the study. For the longitudinal part, we only
compared the patients who attended the second visit with their baseline exploration. We performed
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four comparisons as follows: Control baseline vs. control follow-up, control baseline vs. ALS baseline,
control follow-up vs. ALS follow-up, and ALS baseline vs. ALS follow-up. To verify any asymmetries
between right eyes (RE) and left eyes (LE) in the OCT, a Wilcoxon test was also performed. To correlate
functional and anatomical values with ALSFR-R, a Spearman rho test was employed.
Data were reported as mean values ± SD. All p-values were corrected using Bonferroni correction.
A p-value < 0.05 was considered statistically significant.
3. Results
Demographic and clinical data of ALS patients and control groups are shown in Table 1.
The duration of the illness from the diagnosis to the ophthalmological evaluation ranged from
1 to 18 months (10.80 ± 5.5 months). All patients had a fast-progressive disease; therefore, half of them
could not attend the second exploration due to poor health condition or death.
3.1. ALSFRS-R
The ALSFRS-R score showed statistically significant differences in the comparisons between
control baseline (48.00 ± 0.00) vs. ALS baseline (29.50 ± 14.89) and control follow-up (48.00 ± 0.00) vs.
ALS follow-up (35.6 ± 14.08) (Table 1).
3.2. Best-Corrected Visual Acuity (BCVA)
No significant differences were found in BCVA in the Snellen chart in any of the comparisons
between groups (Table 1).
3.3. Visual Field (VF)
Overall, in VF parameters, we did not find statistically significant differences. We only found a
statistical difference in the percentage of fixation losses (% FL) in the comparison of ALS baseline vs.
ALS follow-up (Table 1).
3.4. Optical Coherence Tomography (OCT)
The comparison between control baseline vs. control follow-up did not show statistical differences
in the OCT parameters (MT, GCC, pRNFL).
3.5. Macular Thickness (MT)
The ALS baseline group showed a significant increased thickness in the inferior (326.91 ± 15.34)
and temporal (315.85 ± 15.34) areas of IMR compared with the control baseline group (inferior =
319.00 ± 12.54; temporal = 307.32 ± 12.49) (p < 0.05; both instances). The comparison between ALS
baseline vs. ALS follow-up revealed a significant thinning in the inferior areas of IMR (ALS baseline =
326.91 ± 15.34 and ALS follow-up = 320.00 ± 11.88) and OMR (ALS baseline = 274.42 ± 14.20 and ALS
follow-up = 264.40 ± 16.34). Non-significant differences were observed in the comparison between
control follow-up vs. ALS follow-up (Figures 2 and 3; Table 2).
3.6. Ganglion Cell Complex (GCC)
Non-significant changes were found in the GCC thickness in any of the comparisons analyzed in
the study (Table 3).
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Table 1. Demographic data, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, and visual field.
Control ALS p-Value
Spearman
Correlation
ALSFRS-R
p-Value
Spearman
Correlation
Baseline Follow-Up Baseline Follow-Up
Control
Baseline vs.
Control
Follow-Up
Control
Baseline vs.
ALS
Baseline
Control
Follow-Ip
vs. ALS
Follow-Up
ALS
Baseline vs.
ALS
Follow-Up
n = 38 n = 38 n = 20 n = 10
Gender
(Male/Female) 9/10 7/1 12/8 4/6
Mean ± SD
BCVA ** 0.98 ± 0.06 0.98 ± 0.04 0.90 ± 0.16 0.91 ± 0.13 0.487 0.230 0.146 0.354 0.317 0.173
AGE 44.74 ± 11.81 45.54 ± 12.47 51.10 ± 9.89 51.30 ±10.02 1.000 0.044 0.250 0.157 (−0.156) 0.338
IOP ** 15.08 ± 2.22 15.31 ± 1.89 15.75 ± 1.99 15.20 ± 1.48 0.146 0.365 0.979 0.564 (−0.407) 0.075
ALSFRS-R ** 48.00 ± 0.00 48.00 ± 0.00 29.50 ± 14.89 35.6 ± 14.08 1.000 <0.001 <0.001 0.068 —— ——
VFI ** 98.63 ± 1.55 99.13 ± 1.09 95.00 ± 8.51 94.63 ± 10.08 0.138 0.388 0.084 0.999 (−0.047) 0.852
MD ** (−0.76) ± 1.68 (−0.05) ± 1.09 (−1.77) ± 3.74 (−2.66) ± 4.71 0.161 0.902 0.086 0.148 0.0854 0.736
PSD ** 1.76 ± 0.75 1.68 ± 0.62 2.68 ± 2.20 2.87 ± 2.96 0.877 0.297 0.257 0.896 (−0.058) 0.818
% FL ** 22.87 ± 28.99 28.23 ± 31.92 28.12 ± 35.06 10.21 ± 12.56 0.615 0.679 0.150 0.037 (−0.052) 0.839
% FN ** 1.45 ± 2.80 2.19 ± 3.04 3.06 ± 4.02 3.5 ± 3.29 0.143 0.407 0.315 0.609 (0.152) 0.546
% FP ** 2.68 ± 3.50 3.25 ± 4.07 3.44 ± 4.19 1.5 ± 2.27 0.850 0.643 0.287 0.165 (−0.131) 0.605
** Non parametric. Data are expressed as mean ± standard deviation (SD) (except sex). Numbers in bold denote p < 0.05 after Bonferroni correction. BCVA: Best-corrected visual acuity;
IOP: Intraocular pressure; ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. Parameters that measure retinal sensitivity: VFI:
Visual field index; MD: Mean deviation (dB); PSD: Pattern standard deviation. Parameters that measure visual field reliability: % FL: Percentage of fixation losses; % FN: Percentage of false
negative errors; % FP: Percentage of false positive errors.
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patients. ALS baseline (n = 20) vs. ALS follow-up (n = 10): A statistically significant thinning of
inferior areas of the inner and outer m cular ri g in ALS follow-up patients. HC: Healthy control;
ALS: Amyot ophic lateral sclerosis, B: B seline, F: F llow-up, OCT: Optic coherence tomography; CMT:
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Table 2. Analysis of macular thickness measures by OCT between ALS and control group.
Control ALS p-Value
Spearman
Correlation
ALSFRS-R
p-Value
Spearman
Correlation
Baseline Follow-Up Baseline Follow-Up Control
Baseline
vs. Control
Follow-Up
Control
Baseline
vs. ALS
Baseline
Control
Follow-Up
vs. ALS
Follow-up
ALS
Baseline
vs. ALS
Follow-Up
Macular Analysis (µm) n = 38 n = 38 n = 20 n = 10
Mean ± SD
Fovea o CMT 261.42 ± 21.31 255.81 ± 23.61 262.10 ± 26.29 274.90 ± 25.32 0.244 1.000 0.567 0.335 0.275 0.241
IMR
Superior 320.55 ± 12.30 315.31 ± 12.06 327.55 ± 15.31 322.20 ± 12.63 0.526 0.435 1.000 0.166 0.077 0.746
Temporal 307.32 ± 12.49 303.06 ± 14.21 315.85 ± 15.34 313.40 ± 13.38 0.705 0.049 1.000 0.160 0.079 0.741
Nasal 323.40 ± 13.99 319.13 ± 15.15 330.35 ± 16.00 327.40 ± 10.93 0.794 0.510 1.000 0.397 0.159 0.502
Inferior 319.00 ± 12.54 314.88 ± 14.58 326.91 ± 15.34 320.00 ± 11.88 0.660 0.029 1.000 0.002 0.000 0.852
OMR
Superior 280.30 ± 10.95 279.06 ± 11.38 279.65 ± 14.39 271.00 ± 14.73 0.444 1.000 0.418 0.161 (−0.121) 0.613
Temporal 260.05 ± 10.04 256.63 ± 6.42 264.58 ± 13.90 261.20 ± 12.54 0.937 0.912 0.872 0.327 (−0.160) 0.498
Nasal 298.97 ± 13.46 295.38 ± 14.39 297.49 ± 24.05 292.20 ± 17.51 0.649 1.000 1.000 0.652 0.057 0.812
Inferior ** 269.74 ± 12.84 269.31 ± 9.44 274.42 ± 14.20 264.40 ± 16.34 0.183 0.819 1.000 0.031 (−0.230) 0.329
Cube Volume 10.08 ± 0.41 10.04 ± 0.29 10.14 ± 0.49 10.00 ± 0.41 0.309 1.000 0.292 0.120 (−0.104) 0.661
Cube average
thickness 279.58 ± 11.23 279.06 ± 7.83 281.70 ± 13.79 277.70 ± 11.70 0.188 1.000 0.181 0.135 (−0.100) 0.674
** No parametric. Data are expressed as mean ± SD. Numbers in bold indicate p < 0.05 after Bonferroni correction. IMR: Inner macular ring; OMR: Outer macular ring; CMT: Central
macular thickness.
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Table 3. Analysis of ganglion cell complex measures by OCT between ALS and control group.
GCC Analysis (µm)
Control ALS p-Value
Spearman
Correlation
ALSFRS-R
p-Value
Spearman
Correlation
Baseline Follow-Up Baseline Follow-Up Control
Baseline
vs. Control
Follow-Up
Control
Baseline
vs. ALS
Baseline
Control
Follow-Up
vs. ALS
Follow-Up
ALS
Baseline
vs. ALS
Follow-Up
n = 38 n = 38 n = 20 n = 10
Mean ± SD
Superior Central ** 81.63 ± 6.18 80.88 ± 7.62 78.70 ± 13.12 76.10 ± 10.04 0.999 1.000 1.000 0.805 (−0.179) 0.450
Temporal ** 79.08 ± 8.09 78.94 ± 4.92 77.80 ± 9.36 76.00 ± 10.03 0.588 1.000 1.000 0.601 0.020 0.934
Nasal 82.68 ± 6.98 82.13 ± 5.81 80.10 ± 10.80 77.50 ± 9.99 0.458 1.000 1.000 0.957 0.103 0.667
Inferior
Central 80.53 ± 6.90 80.75 ± 4.67 80.35 ± 9.69 73.70 ± 12.15 0.989 1.000 0.407 0.070 (−0.237) 0.314
Temporal 81.40 ± 5.53 80.25 ± 4.68 81.00 ± 10.05 77.30 ± 9.81 0.327 1.000 1.000 0.212 (−0.196) 0.407
Nasal 81.32 ± 7.65 80.50 ± 4.90 77.20 ± 11.28 75.20 ± 12.21 0.873 1.000 0.872 0.284 0.085 0.721
GCL (µm)
thickness
Average 81.18 ± 6.20 80.56 ± 5.20 79.15 ± 9.50 76.00 ± 10.30 0.592 1.000 1.000 0.336 (−0.011) 0.962
Minimum ** 78.90 ± 6.13 78.06 ± 5.70 72.70 ± 15.04 74.00 ± 11.74 0.184 1.000 1.000 0.347 0.389 0.090
** No parametric. Data are expressed as mean ± SD. Numbers in bold indicate p < 0.05 after Bonferroni correction. ALS: Amyotrophic lateral sclerosis; OCT: Optical coherence tomography;
GCC: Ganglion cell complex; GCL: Ganglion cell layer; µm: Microns.
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3.7. Peripapillary Retinal Nerve Fiber Layer (pRNFL)
The comparison between ALS baseline vs. ALS follow-up showed significant thinning in the
inferior (ALS baseline = 116.65 ± 25.08 and ALS follow-up = 101.20 ± 26.62) and superior (ALS baseline
= 104.80 ± 23.80 and ALS follow-up = 93.50 ± 24.38) quadrants, and in sectors H3 (ALS baseline = 60.30
± 13.82 and ALS follow-up = 51.90 ± 10.40), H5 (ALS baseline = 102.40 ± 35.00 and ALS follow-up =
80.30 ± 17.93), H6 (ALS baseline = 122.75 ± 37.06 and ALS follow-up = 99.00 ± 31.24), and H12 (ALS
baseline = 101.50 ± 31.37 and ALS follow-up = 81.20 ± 26.15); and an increased thickness in sector H8
(ALS baseline = 67.35 ± 18.23 and ALS follow-up = 69.00 ± 18.74) (p < 0.05 in all instances, except for
H6, p < 0.001; Table 4 and Figure 4).
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Table 4. Analysis of peripapillary retinal nerve-fiber layer measures by OCT between ALS and control group.
Peripapillary Analysis (µm)
Control ALS p-Value
Spearman
Correlation
ALSFRS-R
p-Value
Spearman
Correlation
Baseline Follow-Up Baseline Follow-Up Control
Baseline
vs. Control
Follow-Up
Control
Baseline
vs. ALS
Baseline
Control
Follow-Up
vs. ALS
Follow-Up
ALS
Baseline
vs. ALS
Follow-Up
n = 38 n = 38 n = 20 n = 10
Mean ± SD
Average RNFL Thickness 94.84 ± 12.88 95.69 ± 13.82 88.00 ± 2.60 79.90 ± 13.75 0.572 0.659 1.000 0.073 (−0.334) 0.150
Peripapillary
RNFL
Quadrants (µm)
Superior 112.90 ± 18.33 117.38 ± 21.54 104.80 ± 23.80 93.50 ± 24.38 0.578 0.921 0.093 0.049 (−0.140) 0.555
Temporal 64.95 ± 10.09 65.88 ± 7.21 64.35 ± 12.64 63.50 ± 15.81 0.935 1.000 0.742 0.100 0.362 0.117
Inferior 130.85 ± 22.27 129.75 ± 24.70 116.65 ± 25.08 101.20 ± 26.62 0.074 0.447 1.000 0.001 (−0.527) 0.017
Nasal 71.55 ± 14.87 69.94 ± 12.92 68.75 ± 17.42 61.30 ± 12.29 0.986 1.000 0.659 0.060 (−0.062) 0.795
Peripapillary
RNFL Sectors
(µm)
H1 RE/H11 LE 100.87 ± 20.30 100.94 ± 26.74 90.40 ± 22.74 84.30 ± 29.35 0.070 0.567 1.000 0.781 (−0.056) 0.814
H2 RE/H10 LE 90.11 ± 25.28 92.63 ± 25.95 79.65 ± 23.86 75.10 ± 21.01 0.864 0.645 0.962 0.157 0.117 0.624
H3 RE/H9 LE 56.76 ± 10.91 55.75 ± 6.59 60.30 ± 13.82 51.90 ± 10.40 0.452 1.000 0.330 0.034 (−0.318) 0.172
H4 RE/H8 LE 63.82 ± 13.33 61.75 ± 10.99 65.55 ± 20.61 56.90 ± 12.88 0.566 1.000 1.000 0.320 (−0.019) 0.937
H5 RE/H7 LE 111.37 ± 30.21 110.38 ± 22.80 102.40 ± 35.00 80.30 ± 17.93 0.635 1.000 0.126 0.038 (−0.647) 0.002
H6 OU 148.16 ± 32.02 149.19 ± 30.94 122.75 ± 37.06 99.00 ± 31.24 0.091 0.109 0.510 <0.001 (−0.521) 0.018
H7 RE/H5 LE 133.42 ± 26.05 129.50 ± 34.27 124.50 ± 30.54 123.50 ± 36.77 0.282 1.000 1.000 0.624 0.101 0.673
H8 RE/H4 LE 65.13 ± 12.86 65.13 ± 11.04 67.35 ± 18.23 69.00 ± 18.74 0.837 1.000 1.000 0.024 0.488 0.029
H9 RE/H3 LE 51.18 ± 8.79 53.38 ± 8.80 50.45 ± 9.59 47.50 ± 10.47 0.369 1.000 0.366 0.286 (−0.009) 0.970
H10 RE/H2 LE 78.45 ± 16.84 79.19 ± 17.05 75.20 ± 16.95 74.00 ± 21.39 0.450 1.000 1.000 0.538 0.029 0.904
H11 RE/H1 LE 129.92 ± 33.30 125.50 ± 48.73 117.25 ± 25.27 114.70 ± 29.59 0.307 0.629 0.924 0.747 (−0.098) 0.680
H12 OU 108.63 ± 23.70 119.13 ± 20.47 101.50 ± 31.37 81.20 ± 26.15 0.350 1.000 0.060 0.013 (−0.335) 0.149
Data are expressed as mean ± SD. Numbers in bold denote p < 0.05 after Bonferroni correction. ALS: Amyotrophic lateral sclerosis. H: Clock-hour position; RNFL: Retinal nerve-fiber layer;
C/D: Cup-to-disc.
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3.8. Interocular Asymmetry
Overall, we found significant interocular asymmetries between LE and RE in:
(1) The ALS baseline group in the inferior-nasal area of GCC (RE: 80.60 ± 7.01 and LE: 73.80 ±
13.93 µm, p = 0.042) and in the sectors H7 (RE: 133.00 ± 24.69 and LE: 116.00 ± 34.62 µm, p = 0.022)
and H9 (RE: 53.90 ± 11.51 and LE: 47.00 ± 5.93 µm, p = 0.020).
(2) The ALS follow-up group: In the supero-nasal quadrant of the GCC (RE: 79.00 ± 9.27 and LE:
76.00 ± 11.53 µm, p = 0.043), in the temporal quadrant of pRNFL (RE: 68.40 ± 16.04 and LE: 58.60
± 15.66 µm, p = 0.039), and in sectors H8 (RE: 75.00 ± 18.55 and LE: 63.00 ± 18.87 µm, p = 0.043)
and H9 (RE: 50.80 ± 12.40 and LE: 44.20 ± 8.11 µm, p = 0.043).
3.9. Spearman Correlations between OCT Measurements and ASLFRS-R Score
In ALS baseline, neither functional (BCVA and VF) nor macular OCT parameters (MT, GCC)
correlated with the ALSFRS-R score. However, some pRNFL OCT parameters correlated with
ALSFRS-R (p < 0.05) in the inferior quadrant (ρ = −0.527) and sectors H5 (ρ = −0.647), H6 (ρ = −0.521),
and H8 (ρ = +0.488) (Tables 1–4 and Figure 5).
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4. Discussion
ALS is considered a complex neurodegenerative disease, comprising motor and extra-motor
symptoms such as cognitive impairment, behavioral deficits, abnormalities in both brainstem auditory
and visual evoked potentials, and subtle visual defects [8,15,16,40,51]. Few studies, especially those
using the OCT to determine visual anomalies, relate ALS with the visual system [7,16,40–45,52–55]
because patients do not complain of visual problems, which are overshadowed by motor and respiratory
symptoms. In this study, BCVA, VFs, and OCT were analyzed in patients with sporadic ALS and a
spinal onset. The analyses were performed in a baseline study (n = 20) and in a 6-month follow-up,
where only data of patients who were able to attend the second examination were considered (n = 10).
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The degree of neurological disability was determined using ALSFRS-R [6]. In the ALS group
(baseline and follow-up), ALSFRS-R was significantly decreased compared with the control group
(baseline and follow-up). However, in the comparison between ALS baseline vs. ALS follow-up, the
ALSFRS-R showed a false improvement, because five patients with worse ALSFRS-R scores could not
attend the second exploration due to poor health conditions or death.
In ALS patients (baseline and follow-up), we found a non-significant BCVA decrease compared
with controls (baseline and follow-up), and none of the patients had complained of visual symptoms.
In ALS patients compared with controls (baseline and follow-up in both groups), we did not find
significant differences in the VF parameters, except in the percentage of fixation loss. We think that this
difference could be due to two factors: Patients who were experiencing more neurological disability did
not participate in the second exploration, thus there were fewer patients in the ALS-follow-up (n = 10)
than in ALS-baseline (n = 20) group. As no studies analyzing VFs in ALS patients were available,
we applied the criteria used to conduct VF in Parkinson disease (PD) patients [49]. The ALS patients
have worse reliability indicators, such as a higher rate of fixation losses, as well as false positives and
negatives, than the control group. In our study, ALS patients experienced difficulties, especially with
handwriting and salivation in the ALSFRS-R. Both problems could affect the execution of the VF test
due to the difficulty in maintaining the correct posture and pushing the button of the campimeter.
Thus, it appears that the VF would not be an adequate test to evaluate ALS patients.
In the OCT analysis, we found retinal thickness changes in ALS. The MT in temporal and inferior
IMR areas was significantly thickened in the ALS baseline group compared with the control baseline
group. Other authors have detected non-significant increased thickness in the retina of these patients,
especially in the outer plexiform layer (OPL) [7,40,41]. This macular increased thickness has also
been found in other neurodegenerative diseases such as early Alzheimer disease (AD) [34] or Down’s
syndrome [31]. We hypothesize that the significant increase in MT in temporal and inferior IMR
areas observed in our ALS patients could be caused by a process of protein aggregation [42,52] and/or
neuroinflammation, in which microglia have an important role in ALS pathogenesis [56]. Activated
microglia exhibit morphological changes (retraction of processes and enlargement of the soma), migrate,
and proliferate. Thus, microglia could be the cause of the increased thickness observed in some
retinal areas in our study. Microglial activation has been reported in AD and PD patients in the brain
and retina, and only in the brain in ALS patients in relation to protein aggregates and degenerated
neurons [42,52,57–60]. Ringer et al. analyzed microglia in retinal sections in a mice ALS experimental
model SOD1G93A, and did not detect these changes [61]. On the other hand, in a recent study,
in a mouse model of ALS (lacking Ranbp2 in motorneurons and retinal ganglion cells) in retinal
whole-mounts, microglial activation was demonstrated [62]. Discrepancies between both studies
can be due to the different methods used to study the retinal microglia. Ringer et al.’s [61] study
used retinal sections whereas Cho et al.’s [62] study evaluated the microglial in retinal whole-mounts.
The whole-mounts can allow a more reliable study of the microglial activation signs because microglial
cells can be observed entirely. In addition, the increased thickness observed in our study could also be
due to alterations in axonal transport. It has been proposed that axonal transport defects constitute
one early molecular pathological mechanism in ALS mouse models [63]. Moreover, motorneurons rely
particularly on mitochondria to buffer calcium and reduce the numbers of axonal mitochondrial due to
the impairment of axonal transport and the disruption of calcium homeostasis. These changes reduce
microtubule stability, worsening the bind of motor proteins to the microtubules, and thus, axonal
transport enters in a vicious circle [64]. These observations suggest that defects in axonal transport
could be responsible for the increase in soma size and the axonal calibre of retinal ganglion cells, which
could produce the increased thickness observed by OCT in our study.
Roth et al. [7] did not find significant alterations in the thickness of the optic nerve in ALS patients
compared with a control group using OCT. However, in our study comparing ALS baseline vs. ALS
follow-up, we found significant thinning, both in MT (inferior IMR and OMR areas) and pRNFL
(superior and inferior quadrants and in sectors H3, H5, H6, and H12). Other studies using OCT have
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also demonstrated a thinning of the MT and pRNFL in these patients [40–45]. Volpe et al. [42] reported
that in ALS patients compared with controls, the total macular volume was significantly thinner and
37.5% of ALS patients had a pRNFL average below the first percentile. They concluded that the total
MT and pRNFL thickness were inversely correlated with the duration of the disease. In that study,
the histopathological analysis showed a loss of retinal ganglion cell axons, which could explain the
macular thinning observed using OCT [42]. Finally, Rohani et al. [45] suggested that the thinning of the
pRNFL could be related to Wallerian degeneration secondary to the death of cortical neurons. Some
studies [62] [16] showed a functional deficit in the sensory processing of the visual pathway to the brain
measured by visual evoked potentials (VEPs), both in ALS patients and animal models. Cho et al. [62]
found a delay in the latency of VEPs in an ALS animal model (lacking Ranbp2 in motorneurons
and retinal ganglion cells), before changes of motor behavior occurred. This fact supports a delay
in the transmission from the optic nerve to the visual cortex. Accordingly, Munte et al. [16] found
electrophysiological evidence of a cortical involvement including visual areas in ALS patients.
Our results suggest that the MT increases in the temporal and inferior IMR sectors could be
the first change found in the retina at the beginning of the disease. These results agree with the
observations found in the early stages of AD, where macular increased thickness was also found [34].
In the longitudinal study (ALS baseline vs. ALS follow-up), the evolution from an increased thickness
to a thinning, both in MT and pRNFL thickness, is remarkable. These changes in the thickness of
both the macula and the pRNFL in the progression of ALS could explain why there are no significant
differences between the baseline and follow-up ALS, since there could be a transition from thickening
to thinning with an intermediate stage of normal thickness in the retina.
Differences found between our study and others in OCT measurements [7,40–43,45,52] could
be due to the early stages of ALS in our patients. The duration of the disease in our patients (10.80
± 5.5 months, ranging from 1 to 18 months) was shorter than in other published studies, including
Roth et al. (42 ± 34 months, ranging from 7 to 166 months) [7], Ringelstein et al. (22.3 ± 22.5 months,
ranging from 3 to 120 months) [40], Hübers et al. (ranging from 2 to 98 months) [41], Simonett et al.
(43.2 ± 43.4 months, ranging from 10 to 197 months) [43], and Rohani et al. (14.5 ± 11.3 months) [45].
Therefore, classifying these patients according to the duration of the disease is important to obtain a
better knowledge of the disease.
Discrepancies among different studies could also be due to: (1) The low number of participant
patients, mainly because most of them do not complain of visual problems, and (2) ALS is a
heterogeneous disease [41]. However, despite the lack or the low prevalence of visual problems, most
studies concluded that these patients underwent retinal changes [40–45,52,53].
In the CNS, an asymmetric involvement in ALS has been suggested [65–68]. Rohani et al. [45]
noticed that a reduction in the pRNFL thickness only present in the LE in ALS patients, especially in the
superior and nasal quadrants. Our observations were similar. In the ALS baseline group, LE thicknesses
were thinner than those in the RE, both in the macular and pRNFL areas, being statistically significant
in the inferior-nasal quadrant of GCC and in sectors H7 and H9 of the pRNFL sectors. In the ALS
follow-up group, pRNFL thickness was thinner in the LE in the temporal quadrant and in sectors H8
and H9.
Some studies using OCT in ALS patients did not find a correlation between OCT parameters and
ALSFRS-R score [7,40–42,44]. However, Simonett et al. [43] found a correlation between the thinning of
the macular area and worsening pulmonary function tests. Rohani et al. [45] found a direct correlation
between ALSFRS-R score and average pRNFL thickness in most quadrants. In our study, the ALS
baseline group showed a moderate correlation between OCT pRNFL parameters and the ALSFRS-R
score. We found an inverse correlation in the inferior quadrant and sectors H5 and H6, and a direct
correlation in sector H8. Notably, in these quadrants and sectors, significant pRNFL thickness changes
were also found in the comparison of ALS baseline with ALS follow-up (Table 4 and Figure 5).
One of the most important contributions of this work was the follow-up study. To the best of
our knowledge, this is the first ophthalmological longitudinal study in ALS patients. The scarcity
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of follow-up studies could be due to the difficulty of following up with ALS patients due to their
neurological disability. One of the main limitations of our study is the low number of patients because
of the restrictive inclusion criteria. Another limitation is the low number of patients who could attend
the second exploration. Therefore, further longitudinal studies with more patients are needed.
5. Conclusions
In conclusion, in ALS patients, OCT was the only ophthalmologic exploratory method that showed
the first significant changes in the anterior visual system. The analysis of the OCT showed: (1) In
ALS baseline vs. control baseline, a significant increased macular thickness in the temporal and the
inferior areas of the inner macular ring; (2) in ALS follow-up vs. ALS baseline, a significant macular
thinning in the inferior areas of the inner and outer macular ring; (3) in ALS follow-up vs. ALS
baseline, a pRNFL significant thinning in the superior and inferior quadrants and H3, H5, H6, and
H12; and (4) ALS patients showed a moderate correlation between some OCT pRNFL parameters and
the ALSFRS-R score. The retina is a window to the central nervous system. Thus, OCT could be used
as a complementary and clinical tool for the diagnosis and prognosis of ALS (and in particular, of fast
progressing ALS).
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